Regeneron Pharmaceuticals (REGN)
NASDAQHealth CareBiotechnologySnapshot 2026-07-08
$662.88-1.97%
Close 2026-07-08 · 1-day change
Reading REGN? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track REGN free→NASDAQHealth CareBiotechnologySnapshot 2026-07-08
Reading REGN? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track REGN free→Regeneron grows sales about 12% a year with new drug launches. Profit margins stay strong near 78%. The company controls costs and tax rates well. FDA fast-track programs speed product approvals.
Disappointing trial data and legal setbacks could hurt future sales. Profit margins may fall below guidance. Revenue growth could slow below 7%.
The price is about 8% below our fair value near $733. Analysts expect roughly 12% revenue growth. Our fair value is 9% below the Street median, reflecting some caution.
Breaks if: Effective tax rate rises above 14% in FY26
Regeneron aims to control its GAAP effective tax rate within the guided range.
Stated in 3 of last 3 quarters. The guidance for the GAAP effective tax rate is 12%-14% for 2026. The company has consistently provided guidance within this range, with previous guidance for 2025 being 11%-13%. This indicates a recurring focus on controlling tax expenses, with limited progress in achieving the lower end of the 2026 guidance range.
Breaks if: Gross margin falls below 77% in FY26
Regeneron aims to maintain its GAAP gross margin on net product sales within the guided range.
Stated in 3 of last 3 quarters. The guidance for GAAP gross margin on net product sales is 77%-80% for 2026. The company has consistently provided guidance within this range, indicating a focus on maintaining cost efficiency. However, the actual margin performance for 2025 was approximately 82%, showing limited progress in achieving the lower end of the 2026 guidance range.
Breaks if: Pipeline progress stalls or FDA fast-track designations are lost
Breaks if: YoY revenue growth falls below 7% in FY26
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“GAAP effective tax rate 12%-14% Unchanged”
“GAAP effective tax rate 11%-13% Approximately 14%”
“GAAP effective tax rate 9%-11%”
“GAAP gross margin on net product sales 79%-80% 77%-78%”
“GAAP gross margin on net product sales Approximately 83% Approximately 82%”
“GAAP gross margin on net product sales 83%-84% Approximately 83%”